Difference between revisions of "Ponatinib (Iclusig)"
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGF inhibitors" to "Category:VEGFR inhbitors") |
Warner-admin (talk | contribs) m (Text replacement - "Category:VEGFR inhbitors" to "Category:VEGFR inhibitors") |
||
| Line 38: | Line 38: | ||
[[Category:RET inhibitors]] | [[Category:RET inhibitors]] | ||
[[Category:SRC inhibitors]] | [[Category:SRC inhibitors]] | ||
| − | [[Category:VEGFR | + | [[Category:VEGFR inhibitors]] |
[[Category:PDGFR inhibitors]] | [[Category:PDGFR inhibitors]] | ||
Revision as of 21:19, 2 February 2018
General information
Class/mechanism: Tyrosine kinase inhibitor with multiple targets, including Bcr-Abl tyrosine kinase, the constitutively active tyrosine kinase resulting from the Philadelphia chromosome abnormality in CML, as well as VEGFR, PDGFR, FGFR, the SRC kinases, KIT, EPH receptors, RET, TIE2, and FLT3. Ponatinib is active against the Bcr-Abl T315I mutation.[1][2][3][4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Patient counseling information can be found on pages 16-17 of the Ponatinib (Iclusig) package insert[1]
History of changes in FDA indication
- 12/14/2012: FDA approved "for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."
- 10/31/2013: Suspended by FDA because of the risk of life-threatening blood clots and severe narrowing of blood vessels.
- 12/20/2013: REMS program put in place and medication is once again available.
- 11/29/2016: FDA granted full approval "for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) for whom no other tyrosine kinase inhibitor therapy is indicated; and for the treatment of adult patients with T315I–positive CML (chronic phase, accelerated phase, or blast phase) or T315I-positive, Philadelphia chromosome–positive ALL."
Also known as
- Code name: AP24534
- Generic name: ponatinib hydrochloride
- Brand name: Iclusig
References
- Drug index
- Oral medications
- Mutation-specific medications
- Kinase inhibitors
- Bcr-Abl inhibitors
- FGFR inhibitors
- FLT3 inhibitors
- KIT inhibitors
- RET inhibitors
- SRC inhibitors
- VEGFR inhibitors
- PDGFR inhibitors
- B-cell acute lymphoblastic leukemia medications
- Chronic myelogenous leukemia medications
- REMS program
- Drugs FDA approved in 2012
- PMDA approved drugs